Strategies to overcome the polycation dilemma in drug delivery

被引:109
|
作者
Bernkop-Schnuerch, Andreas [1 ,2 ]
机构
[1] Univ Innsbruck, Ctr Chem & Biomed, Dept Pharmaceut Technol, Inst Pharm, Innrain 80-82,Room L-04-231, A-6020 Innsbruck, Austria
[2] ThioMatrix Forsch & Entwicklungs GmbH, Trientlgasse 65, A-6020 Innsbruck, Austria
关键词
polycation dilemma; drug delivery; polycations; chitosan; polyethyleneimine; cell penetrating peptides; cationic lipids; POLYELECTROLYTE COMPLEX-FORMATION; POTENTIAL-CHANGING NANOPARTICLES; CELL-PENETRATING PEPTIDES; TRIGGERED CHARGE-REVERSAL; IN-VITRO EVALUATION; SURFACE-CHARGE; TUMOR MICROENVIRONMENT; POLYMERIC MICELLES; HYALURONIC-ACID; PH;
D O I
10.1016/j.addr.2018.07.017
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Because of polycationic auxiliary agents such as chitosan, polyethyleneimine and cell penetrating peptides as well as cationic lipids assembling to polycationic systems, drug carriers can tightly interact with cell membranes exhibiting a high-density anionic charge. Because of these interactions the cell membrane is depolarized and becomes vulnerable to various uptake mechanisms. On their way to the target site, however, the polycationic character of all these drug carriers is eliminated by polyanionic macromolecules such as mucus glycoproteins, serum proteins, proteoglycans of the extracellular matrix (ECM) and polyanionic surface substructures of non-target cells such as red blood cells. Strategies to overcome this polycation dilemma are focusing on a pH-, redox- or enzyme-triggered charge conversion at the target site. The pH-triggered systems are making use of a slight acidic environment at the target site such as in case of solid tumors, inflammatory tissue and ischemic tissue. Due to a pH shift from 7.2 to slightly acidic mainly amino substructures of polymeric excipients are protonated or shielding groups such as 2,3 dimethylmaleic acid are cleaved off unleashing the underlying cationic character. Redox-triggered systems are utilizing disulfide linkages to bulky side chains such as PEGs masking the polycationic character. Under mild reducing conditions such as in the tumor microenvironment these disulfide bonds are cleaved. Enzyme-triggered systems are targeting enzymes such as alkaline phosphatase, matrix metalloproteinases or hyaluronidase in order to eliminate anionic moieties via enzymatic cleavage resulting in a charge conversion from negative to positive. Within this review an overview about the pros and cons of these systems is provided. (C) 2018 Elsevier B.V. All rights reserved.
引用
收藏
页码:62 / 72
页数:11
相关论文
共 50 条
  • [31] Cancer nanomedicine: Recent developments in drug delivery systems and strategies to overcome eventual barriers to achieve a better outcome
    Henn, Jeferson Gustavo
    Aguirre, Tanira Alessandra Silveira
    Nugent, Michael
    Moura, Dinara Jaqueline
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2024, 91
  • [32] Employing Drug Delivery Strategies to Overcome Challenges Using TLR7/8 Agonists for Cancer Immunotherapy
    Dhruv Varshney
    Sherry Yue Qiu
    Tyler P. Graf
    Kevin J. McHugh
    The AAPS Journal, 23
  • [33] Employing Drug Delivery Strategies to Overcome Challenges Using TLR7/8 Agonists for Cancer Immunotherapy
    Varshney, Dhruv
    Qiu, Sherry Yue
    Graf, Tyler P.
    McHugh, Kevin J.
    AAPS JOURNAL, 2021, 23 (04):
  • [34] Oral delivery of therapeutic peptides:: Barriers and strategies to overcome them
    Bernkop-Schnuerch, Andreas
    JOURNAL OF DRUG TARGETING, 2006, 14 (03) : 107 - 108
  • [35] Strategies to overcome the skin barrier function for the targeted delivery of ibuprofen
    Patel, A.
    Lane, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2014, 134 : S67 - S67
  • [36] The use of TPGS in drug delivery systems to overcome biological barriers
    Luiz, Marcela Tavares
    Di Filippo, Leonardo Delello
    Alves, Renata Carolina
    Sousa Araujo, Victor Hugo
    Duarte, Jonatas Lobato
    Marchetti, Juliana Maldonado
    Chorilli, Marlus
    EUROPEAN POLYMER JOURNAL, 2021, 142
  • [37] Engineering nanoparticles to overcome immunological barriers for enhanced drug delivery
    Malachowski T.
    Hassel A.
    Engineered Regeneration, 2020, 1 : 35 - 50
  • [38] Drug delivery approaches to overcome bacterial resistance to β-lactam antibiotics
    Abeylath, Sampath C.
    Turos, Edward
    EXPERT OPINION ON DRUG DELIVERY, 2008, 5 (09) : 931 - 949
  • [39] DRUG DELIVERY IN DIFFUSE INTRINSIC PONTINE GLIOMA: A BARRIER TO OVERCOME
    van Zanten, S. E. M. Veldhuijzen
    El-Khouly, F. E.
    van Vuurden, D. G.
    Hendrikse, N. H.
    Kaspers, G. L.
    NEURO-ONCOLOGY, 2016, 18 : 64 - 64
  • [40] A novel strategy to overcome the "PEG dilemma" for a peptide-based gene delivery vector
    Loughran, Stephen
    McCarthy, Helen
    McCrudden, Cian
    Donnelly, Ryan
    HUMAN GENE THERAPY, 2015, 26 (09) : A23 - A24